Wolf Haldenstein Adler Freeman & Herz and Levi & Korsinsky filed a stockholder derivative suit Monday in California Southern District Court against Sorrento Therapeutics and members of its board. The complaint arises from the company’s development of STI-1499, intended as an antibody for COVID-19. The defendants are accused of misrepresenting STI-1499 as a viable cure while it was in the early stages of pre-clinical trials. Counsel have not yet appeared for the defendants. The case is 3:21-cv-01331, Chaudhari v. Ji et al.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
